<DOC>
	<DOCNO>NCT00004163</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness trastuzumab treat patient advanced salivary gland cancer .</brief_summary>
	<brief_title>Trastuzumab Treating Patients With Advanced Salivary Gland Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate trastuzumab patient advance metastatic salivary gland cancer . II . Determine time progression patient regimen . III . Determine toxicity trastuzumab patient . OUTLINE : Patients stratify accord histology : intercalated duct ( adenoid cystic carcinoma , acinic cell carcinoma , malignant mixed tumor , polymorphous low grade adenocarcinoma , undifferentiated carcinoma , adenocarcinoma ) v excretory duct ( squamous cell carcinoma , mucoepidermoid carcinoma ) . Patients receive trastuzumab IV 30-90 minute weekly 4 week . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 50 patient ( 25 per stratum ) accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally unresectable metastatic malignancy arise salivary tissue Adenoid cystic carcinoma Polymorphous low grade adenocarcinoma Mucoepidermoid carcinoma Undifferentiated carcinoma Acinic cell carcinoma Squamous cell carcinoma Malignant mixed tumor Adenocarcinoma Unidimensionally measurable disease Overexpression Her2/neu protein PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count great 1999/mm3 Platelet count great 99,999/mm3 Hemoglobin great 8.5 g/dL OR Hematocrit great 25 % Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT le 2 time ULN ( less 5 time ULN liver involvement ) Alkaline phosphatase less 5 time ULN ( restriction bone liver involvement ) Renal : Creatinine le 1.5 time ULN OR Creatinine clearance least 50 % low limit normal Cardiovascular : Must normal cardiac contractility MUGA receive prior anthracyclines ( doxorubicin , daunorubicin , epirubicin ) No congestive heart failure Pulmonary : No chronic obstructive pulmonary disease Other : No prior malignancy past 3 year except curatively treat nonmelanoma skin cancer cervical cancer No significant active illness No uncontrolled diabetes No AIDS Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunologic therapy No concurrent immunologic therapy Chemotherapy : No 2 prior regimen cytotoxic chemotherapy salivary gland cancer No prior doxorubicin 360 mg/m2 No concurrent chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy No concurrent hormonal therapy Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since prior homeopathic , natural , alternative medicine therapy No concurrent homeopathic , natural , alternative medicine therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>salivary gland acinic cell tumor</keyword>
	<keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>salivary gland poorly differentiate carcinoma</keyword>
	<keyword>salivary gland malignant mixed cell type tumor</keyword>
	<keyword>salivary gland adenoid cystic carcinoma</keyword>
</DOC>